Dermatology
Partner With Us
Advertisement

Marlise Luskin, MD, MSCE discusses results of a phase 1 trial

Venetoclax plus inotuzumab ozogramicin for relapsed and refractory ALL: Results of a phase 1 trial

Dana-Farber
Venetoclax plus inotuzumab ozogramicin for relapsed and refractory ALL: Results of a phase 1 trial